1
Shirai Junya, Matsumoto Takahiro, Kamo Izumi: (Ja) ベンゾオキサゼピン誘導体およびその用途, (En) Benzoxazepine derivatives and use thereof. Takeda Pharmaceutical Company, Shirai Junya, Matsumoto Takahiro, Kamo Izumi, TAKASHIMA Hajime, September 12, 2008: WO/2008/108445 (19 worldwide citation)

(EN) Compounds represented by the general formula (I) wherein each symbol is as defined in the description [with the proviso that 9-chloro-7-(1,1-dimethylethyl)-2,3,4,5-tetrahydro-1,4-benz-oxazepine and N-[[(5S)-2-oxo-3-(2,3,4,5-tetrahydro-1,4- benz- oxazepin-7-yl)-5-oxazolidinyl]methyl]acetamide ar ...


2
Ikeura Yoshinori, Shirai Junya, Sugiyama Hideyuki, Nishikimi Yuji, Kamei Taku, Sakauchi Nobuki: Nitrogen-containing heterocyclic compound and use thereof. Takeda Pharmaceutical Company, Ikeura Yoshinori, Shirai Junya, Sugiyama Hideyuki, Nishikimi Yuji, Kamei Taku, Sakauchi Nobuki, TAKASHIMA Hajime, June 11, 2009: WO/2009/072643 (11 worldwide citation)

The present invention relates to a compound represented by the formula wherein ring A is a nitrogen-containing heterocycle optionally further having substituent(s), ring B is an aromatic ring optionally having substituent(s), ring C is a cyclic group optionally having substituent(s), R1 is a hydroge ...


3
Shirai Junya, Kusumoto Tomokazu, Nagamiya Hiroyuki, Kamo Izumi: Fused heterocyclic compound and use thereof. Takeda Pharmaceutical, January 28, 2009: EP2018863-A1 (8 worldwide citation)

The present invention relates to a serotonin 5-HT 2C receptor activator containing a compound represented by the formula wherein ring A is a 5- or 6-membered aromatic heterocycle optionally having substituent(s), and ring B is a 7- to 9-membered ring optionally having substituent(s) other than an ox ...


4
Shirai Junya, Kusumoto Tomokazu, Nagamiya Hiroyuki, Kamo Izumi: (Ja) 縮合複素環化合物およびその用途, (En) Fused heterocyclic compound and use thereof. Takeda Pharmaceutical Company, Shirai Junya, Kusumoto Tomokazu, Nagamiya Hiroyuki, Kamo Izumi, TAKASHIMA Hajime, November 22, 2007: WO/2007/132841 (7 worldwide citation)

(EN) Disclosed is a serotonin 5-HT2C receptor activator comprising a compound represented by the formula below or a salt or prodrug thereof: (I) wherein the ring A represents a 5- or 6-membered aromatic heterocyclic ring which may have a substituent; and the ring B represents a 7- to 9-membered ring ...


5
YAMAMOTO Satoshi, SHIRAI Junya, OCHIDA Atsuko, FUKASE Yoshiyuki, TOMATA Yoshihide, SATO Ayumu, MIURA Shotaro, YONEMORI Kazuko, KOYAMA Ryokichi: [ja] 複素環化合物, [fr] COMPOSÉ HÉTÉROCYCLIQUE, [en] HETEROCYCLIC COMPOUND. YAMAMOTO Satoshi, SHIRAI Junya, OCHIDA Atsuko, FUKASE Yoshiyuki, TOMATA Yoshihide, SATO Ayumu, MIURA Shotaro, YONEMORI Kazuko, KOYAMA Ryokichi, TAKEDA PHARMACEUTICAL COMPANY, TAKASHIMA Hajime, February 7, 2013: WO/2013/018695 (7 worldwide citation)

[en] To provide a heterocyclic compound which has an RORγt inhibitory effect. A compound represented by formula (I) or a salt thereof. (In the formula, ring A represents an optionally substituted cyclic group; Q represents a bonding hand or the like; R1 represents a substituent; ring B represents a ...


6
YAMAMOTO Satoshi, SHIRAI Junya, FUKASE Yoshiyuki, TOMATA Yoshihide, SATO Ayumu, OCHIDA Atsuko, YONEMORI Kazuko, NAKAGAWA Hideyuki: [ja] 縮合複素環化合物, [fr] COMPOSÉ HÉTÉROCYCLIQUE CONDENSÉ, [en] CONDENSED HETEROCYCLIC COMPOUND. TAKEDA PHARMACEUTICAL COMPANY, TAKASHIMA Hajime, March 28, 2013: WO/2013/042782 (6 worldwide citation)

[en] The purpose of the present invention is to provide a condensed heterocyclic compound having a RORγt inhibitory activity. A compound represented by formula (I') [wherein each symbol is as defined in the description] (wherein 2-(2-((4-cyanophenyl)amino)-2-oxoethoxy)-N-(9-ethyl-9H-carbazol-3-yl)ac ...


7
Matsumoto Takahiro, Nagamiya Hiroyuki, Shirai Junya, Kusumoto Tomokazu: (Ja) 縮合ピリジン誘導体およびその用途, (En) Fused pyridine derivative and use thereof. Takeda Pharmaceutical Company, Matsumoto Takahiro, Nagamiya Hiroyuki, Shirai Junya, Kusumoto Tomokazu, TAKASHIMA Hajime, May 22, 2009: WO/2009/063993 (5 worldwide citation)

(EN) Disclosed is a serotonin 5-HT2c receptor activator containing a compound represented by the formula (I) below or a salt thereof. (In the formula, the symbols are as defined in the description.)(JA)  本発明は、式:[式中、各記号は明細書中と同義を示す]で表される化合物またはその塩を含有してなるセロトニン5-HT2c受容体活性化剤に関する。


8
YAMAMOTO Satoshi, SHIRAI Junya, FUKASE Yoshiyuki, SATO Ayumu, KOUNO Mitsunori, TOMATA Yoshihide, OCHIDA Atsuko, YONEMORI Kazuko, ODA Tsuneo, IMADA Takashi, YUKAWA Tomoya: [ja] 複素環化合物, [fr] COMPOSÉ HÉTÉROCYCLIQUE, [en] HETEROCYCLIC COMPOUND. TAKEDA PHARMACEUTICAL COMPANY, TAKASHIMA Hajime, September 18, 2014: WO/2014/142255 (5 worldwide citation)

[en] Provided is a heterocyclic compound exhibiting an RORγt-inhibiting action. Specifically provided is a compound represented by formula (I) or a salt thereof. [In the formula, Ar indicates partial formulas (1) through (5), Q indicates a bivalent group selected from the group consisting of (Ia) th ...


9
YAMAMOTO SATOSHI , SHIRAI JUNYA , FUKASE YOSHIYUKI , TOMATA YOSHIHIDE , SATO AYUMU , OCHIDA ATSUKO , YONEMORI KAZUKO , NAKAGAWA HIDEYUKI : [fr] COMPOSÉ HÉTÉROCYCLIQUE CONDENSÉ, [de] KONDENSIERTE HETEROCYCLISCHE VERBINDUNG, [en] CONDENSED HETEROCYCLIC COMPOUND. TAKEDA PHARMACEUTICAL , July 30, 2014: EP2759533-A1 (4 worldwide citation)

[en] The present invention provides a fused heterocyclic compound having an ROR t inhibitory action. The present invention relates to a compound represented by the formula (I'): wherein each symbol is as defined in the specification, provided that 2-(2-((4-cyanophenyl)amino)-2-oxoethoxy)-N-(9-ethyl- ...


10
SHIRAI JUNYA, SUGIYAMA HIDEYUKI, KAMEI TAKU, MAEZAKI HIRONOBU: NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME, STICKSTOFFHALTIGE HETEROZYKLISCHE VERBINDUNG UND IHRE VERWENDUNG, COMPOSÉ HÉTÉROCYCLIQUE CONTENANT DE LAZOTE ET SON UTILISATION. TAKEDA PHARMACEUTICAL, June 22, 2011: EP2336105-A1 (4 worldwide citation)

The present invention relates to a compound represented by the formula wherein ring A is a nitrogen-containing heterocycle ring B is an aromatic ring optionally having substituent(s) ring D is an aromatic ring optionally having substituent(s) L is a group represented by the formula R 2 , R 3 , R 4a ...